This year’s CPhI awards attracted more than 200 entries in 19 categories. MJR PharmJet brought forward the MicroJet Reactor Technology for the continuous synthesis of nanoparticles under GMP conditions winning the first prize in the ‘Manufacturing Technology and Equipment’ category.
Munich, Germany, November 20, 2017 / B3C newswire / -- The CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. MJR PharmJet, partner of leon-nanodrugs GmbH in drug development received one of this year’s awards for the highly innovative MicroJet Reactor Technology. leon-nanodrugs is the owner of the MicroJet Reactor Technology for the creation of pharmaceutical nanoparticles and drug delivery systems enabling specific formulations of pharmaceuticals. MJR PharmJet holds a comprehensive patent family covering the technology and collaborates with leon-nanodrugs in the development of innovative drug formulations using leon’s proprietary nanotechnology.
This year’s CPhI awards attracted more than 200 entries in 19 categories. MJR PharmJet brought forward the MicroJet Reactor Technology for the continuous synthesis of nanoparticles under GMP conditions winning the first prize in the ‘Manufacturing Technology and Equipment’ category. This is a strong recognition of the value of the MicroJet Reactor Technology in technology transfer from lab scale to manufacturing scale in manufacturing of nanoparticles.
It is estimated that over 60% of pharmaceutical API’s are poorly soluble in water. leon’s MJR Technology offers formulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability or improving onset of action. The one-step, bottom up, continuous production process approach of the MJR technology enables the development of a wide variety of nanoparticle types, tailored particles sizes and is easily scalable.
Dr. Michael Mehler, CEO of leon-nanodrugs GmbH comments: “We congratulate our partner, MJR PharmJet, for receiving such a prestigious award. This is a great testimony of the potential of the unique attributes of the MicroJet Reactor Technology and confirms our vision to generate added value for therapeutic molecules through specific nano-formulations. In addition to MJR PharmJet with our USA based CDMO CoreRx we can offer our pharmaceutical and biotechnology partners access to this innovative technology.”
